Mereo BioPharma Group PLC (HAM:MAH0)
€ 3.57 -0.09 (-2.46%) Market Cap: 549.25 Mil Enterprise Value: 476.12 Mil PE Ratio: 0 PB Ratio: 8.01 GF Score: 18/100

Mereo Biopharma Group PLC at SVB Leerink Global Healthcare (Virtual) Transcript

Feb 17, 2022 / 01:00PM GMT
Beth Feindt;Scott
SVB Leerink - Analyst

Good morning, everyone. Thank you so much for tuning in for today's fireside chat with Mereo BioPharma as part of the SVB Leerink Global Healthcare Conference. My name is Beth Feindt-Scott; I'm an associate representing SVB's rare disease team. And it's my pleasure today to introduce Mereo's Denise Scots-King (sic - Denise Scots-Knight), CEO; Christine Fox, CFO; John Lewicki, CSO; Jackie Parkin, SVP and Therapeutic Head; and Suba Krishnan, SVP of Clinical Development.

Before we get started, I did want to let the audience know, if you have any questions, you can feel free to write those in at the chat box at the bottom of your screen and I'll be sure to get to that. And with that we can kick off.

Questions & Answers

Beth Feindt;Scott
SVB Leerink - Analyst

The first question I have for you guys is I was wondering if you could maybe just start off by giving us an overview of your recent progress, your priorities for the next 12 months and any sort of key catalyst you

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot